Compare Summit Therapeutics Inc (SMMT) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Financial Select Sector SPDR Fund — how do they compare? Summit Therapeutics Inc trades at $17.52 (market cap $13.79B), while Financial Select Sector SPDR Fund trades at $57.27. The key difference: Financial Select Sector SPDR Fund is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| SMMT | XLF | |
|---|---|---|
Market Cap | $13.79B | — |
Sector | Health | — |
52-Week High | $26.38 | $58.55 |
52-Week Low | $12.43 | $47.80 |
Enterprise Value | $13.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
XLF, the Financial Select Sector SPDR Fund, trades at $57.3, down 1.38% over 24 hours. The technical outlook is neutral overall, with bullish moving averages but neutral oscillators, and key support at $57. Recent news highlights consolidation amid shifting interest rate expectations and fund manager rotation into financials in Q2 2026. The ETF offers exposure to 76 large-cap U.S. financial firms with a low expense ratio of 0.08%.
The outlook for XLF is balanced. Potential upside exists from rising interest rates benefiting banks and institutional inflows, but risks include economic sensitivity and sector volatility. The neutral technical and sentiment signals suggest a wait-and-see approach, with the dividend providing modest income.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
